Clinical Trials Sponsored by Biocerna LLC

Total 10691 results

Biocerna LLC

Unknown

Assessment of Self-Collected Sample Compared to Clinician Collected Sample in COVID-19 and Influenza Program

Subjects Possibly Exposed to COVID-19

United States
Biocerna LLC

Completed

The Impact of Delayed Diagnosis of Alpha-1 Antitrypsin Deficiency

Alpha 1-Antitrypsin Deficiency

United States
Dicerna Pharmaceuticals, Inc.

Terminated

A Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1)

Primary Hyperoxaluria Type 1

Netherlands, Germany
Dicerna Pharmaceuticals, Inc.

Withdrawn

An Extension Study of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATLD)

Alpha 1-Antitrypsin Deficiency

New Zealand
Dicerna Pharmaceuticals, Inc.

Completed

A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2 (PHYOX2)

Kidney Diseases | Urologic Diseases | Genetic Disease | Primary Hyperoxaluria Type 1 (PH1) | Primary Hyperoxaluria Type 2 (PH2)

Poland, United Kingdom, New Zealand, United States, Australia, Canada, France, Germany, Israel, Italy, Japan, Lebanon, Netherlands, Romania, Spain
Dicerna Pharmaceuticals, Inc.

Completed

Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients (PHYOX4)

Primary Hyperoxaluria Type 3

United States, Germany, Netherlands, United Kingdom
Dicerna Pharmaceuticals, Inc.

Completed

Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria

Primary Hyperoxaluria

United States, France, Germany, Netherlands, United Kingdom
Dicerna Pharmaceuticals, Inc.

Terminated

Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma

Hepatocellular Carcinoma

Korea, Republic of, United States, Singapore
Dicerna Pharmaceuticals, Inc.

Terminated

Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma

Multiple Myeloma | PNET | Solid Tumors | Non-Hodgkins Lymphoma | NHL | Pancreatic Neuroendocrine Tumors

United States
Dicerna Pharmaceuticals, Inc.

Completed

Study of Safety and Tolerability of DCR HBVS

Hepatitis B, Chronic

Korea, Republic of, New Zealand, Australia, Thailand, Hong Kong
Dicerna Pharmaceuticals, Inc.
Parexel

Completed

Study of DCR-AUD in Healthy Volunteers

Alcohol Use Disorder (AUD)

United States
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Recruiting

Safety & Efficacy of DCR-PHXC in Patients With PH1/2 and ESRD (PHYOX7)

End Stage Renal Disease | Primary Hyperoxaluria Type 2 | Primary Hyperoxaluria Type 1

Germany, Spain, United States, United Kingdom, Italy, United Arab Emirates, Lebanon, Morocco, France, Romania
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Active, not recruiting

A Study of Belcesiran in Patients With AATLD (ESTRELLA)

Alpha 1-Antitrypsin Deficiency

United Kingdom, United States, Ireland, Belgium, New Zealand, Spain, Netherlands, Portugal, Canada, Australia, France, Austria, Germany, Sweden
Arthritis Northwest PLLC
Epigenesys LLC

Unknown

Identification of Epigenetic Biomarkers for Early Detection of Rheumatic Disease

Arthritis, Rheumatoid

United States
Angle plc
MidLantic Urology, LLC

Terminated

Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System (CHARTER)

Prostate Cancer | Castration-resistant Prostate Cancer | Biochemically Recurrent Prostate Carcinoma | High Risk Prostate Carcinoma

United States
Centre de Pharmacologie Clinique Applique a la...
BIODERMA

Completed

Prevention of Melasma Relapse During Summertime

Melasma
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Recruiting

A Study of DCR-STAT3 in Adults With Solid Tumors

Solid Tumor, Adult | Refractory Tumor

United States
Synochi, LLC
LAC+USC Medical Center

Not yet recruiting

Prospective Placebo-controlled Study of Synochi Scar Spray

Burns Multiple
Derm Research, PLLC
WFH MEDICAL, LLC

Completed

Aczone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Aczone 5% Gel

Acne Vulgaris

United States
Verily Life Sciences LLC
The Emmes Company, LLC; Optos, PLC; Google LLC.; Nikon Corporation

Completed

ARDA Software for the Detection of mtmDR

Diabetic Retinopathy

United States
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Recruiting

Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function (PHYOX8)

Primary Hyperoxaluria Type 3 | Primary Hyperoxaluria Type 2 | Primary Hyperoxaluria Type 1 | Primary Hyperoxaluria

United States, Canada, Lebanon, Turkey, United Kingdom, Germany, Italy, Japan, Poland, Spain, United Arab Emirates
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Completed

Phase 1b Study of DCR-AUD in Healthy Volunteers

Alcohol Use Disorder

United States
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Active, not recruiting

Natural History of Patients With PH3 and a History of Stone Events (PHYOX-OBX)

Primary Hyperoxaluria Type 3

United States, Germany, United Kingdom, Canada, Poland
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Completed

Study of DCR-A1AT in Healthy Adult Volunteers

Alpha 1-Antitrypsin Deficiency

New Zealand, Sweden
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Enrolling by invitation

Long Term Extension Study in Patients With Primary Hyperoxaluria (PHYOX3)

Kidney Diseases | Urologic Diseases | Genetic Disease | Primary Hyperoxaluria Type 1 (PH1) | Primary Hyperoxaluria Type 2 (PH2) | Primary Hyperoxaluria Type 3 (PH3)

United States, France, Germany, Japan, Lebanon, Spain, United Kingdom, Australia, Canada, Italy, Netherlands, Norway, Turkey
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Available

Treatment of Primary Hyperoxaluria Type 1 With Nedosiran

Primary Hyperoxaluria Type 1 (PH1)
MedRegen LLC
Johns Hopkins University; ICON plc

Recruiting

MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients

COVID-19 | ARDS, Human | Regeneration | Stem Cells

United States
Redx Pharma Plc
Merck Sharp & Dohme LLC

Completed

A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2) (KEYNOTE-E86)

Advanced Solid Tumours

United Kingdom, Australia
4D pharma plc
Merck Sharp & Dohme LLC

Terminated

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

Melanoma | Renal Cell Carcinoma | Solid Tumor | Non Small Cell Lung Cancer | Bladder Cancer | Oncology

United States
IVFarma LLC
BridgePharm LLC; GlobalPharma LLC

Completed

Study to Compare Efficacy and Safety of Primapur and Gonal-f in Women for Assisted Reproductive Treatment

Infertility, Female

Russian Federation
Pharmtechnology LLC
ClinPharmInvest, LLC

Not yet recruiting

Bioequivalence Study of Two Formulations of Etoricoxib Tablets 120 mg in Healthy Volunteers Under Fasting Conditions

Bioequivalence

Russian Federation
Pharmtechnology LLC
ClinPharmInvest, LLC

Not yet recruiting

Bioequivalence Study of Two Formulations of Rivaroxaban Tablets 20 mg in Healthy Male Volunteers Under Fed Conditions

Bioequivalence

Russian Federation
Pharmtechnology LLC
ClinPharmInvest, LLC

Completed

Bioequivalence Study of Two Formulations of Atorvastatin Film-coated Tablets 40 mg in Healthy Volunteers Under Fasting Conditions

Bioequivalence

Russian Federation
Pharmtechnology LLC
ClinPharmInvest, LLC

Completed

Bioequivalence Study of Two Formulations of Clopidogrel Film-coated Tablets 75 mg in Healthy Male Subjects Under Fasting Conditions

Bioequivalence

Russian Federation
Pharmtechnology LLC
ClinPharmInvest, LLC

Completed

Bioequivalence Study of Clavamox, Film-coated Tablets, 875 mg + 125 mg Pharmtechnology LLC, Belarus), and Augmentin®, Film-coated Tablets, 875 mg + 125 mg (GlaxoSmithKline Trading CJSC, Russia), in Healthy Volunteers Under Fasting Conditions

Bioequivalence

Russian Federation
Pharmtechnology LLC
ClinPharmInvest, LLC

Completed

Bioequivalence Study of Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml (Pharmtechnology LLC, Belarus), and Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml (GlaxoSmithKline Trading CJSC, Russia), in Healthy Volunteers Under Fasting Conditions

Bioequivalence

Russian Federation
Monsoon Design Studio LLC
Healthark Wellness Solutions LLP

Completed

Study of Evoked Emotional Responses

Emotion, Expressed

India
Pharmtechnology LLC
ClinPharmInvest, LLC

Completed

Bioequivalence Study of Two Formulations of Torasemide Tablet 10 mg in Healthy Volunteers Under Fasting Conditions

Bioequivalence

Russian Federation
AOBiome LLC
bioRASI, LLC

Completed

B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis

Atopic Dermatitis

United States
AOBiome LLC
bioRASI, LLC

Completed

A Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Rosacea

Rosacea

United States
Pharmtechnology LLC
ClinPharmInvest, LLC

Completed

Bioequivalence Study of Two Formulations of Lisinopril Tablet 20 mg in Healthy Volunteers Under Fasting Conditions

Bioequivalence

Russian Federation
BioMendics, LLC
Symbio, LLC

Completed

Efficacy of Topical TolaSure on Acute Induced Wounds in Healthy Participants

Wound Healing

United States
Pharmtechnology LLC
ClinPharmInvest, LLC

Unknown

Bioequivalence Study of Two Formulations of Rivaroxaban Tablets 10 mg in Healthy Male Volunteers in Fasting Conditions

Bioequivalence

Russian Federation
Soniphi LLC
UserWise, LLC

Unknown

Vocal Feature Analysis Algorithm for COVID-19 Detection

COVID-19

United States
Pharmtechnology LLC
ClinPharmInvest, LLC

Completed

A Bioequivalence Study of Two Formulations Lamotrigine 100 mg Tablets and Lamictal 100 mg Tablets in Healthy Adult Volunteers Under Fasting Conditions

Healthy Adults

Russian Federation
Pharmtechnology LLC
ClinPharmInvest, LLC

Completed

Bioequivalence Study of Ibuprofen D, Oral Suspension, 200 mg/5ml and Nurofen®, Oral Suspension 100 mg/5 ml in Healthy Volunteers Under Fasting Conditions

Healthy

Russian Federation
Pharmtechnology LLC
ClinPharmInvest, LLC

Not yet recruiting

Bioequivalence Study of Two Formulations of Sildenafil Tablet 100 mg in Healthy Male Volunteers Under Fasting Conditions

Bioequivalence

Russian Federation
IVFarma LLC
NADIM LLC

Completed

The Safety and Pharmacokinetics of Primapur and Gonal-f

Pharmacokinetics | Absorption | Area Under Curve

Russian Federation
Pharmtechnology LLC
ClinPharmInvest, LLC

Completed

Bioequivalence Study of Montelukast, 5 mg Chewable Tablets (Pharmtechnology LLC, Belarus), and Singulair®, 5 mg Chewable Tablets (Merck Sharp & Dohme B.V., the Netherlands), in Healthy Volunteers Under Fasting Conditions

Healthy Adults

Russian Federation
Immunitor LLC
Ekomed LLC

Unknown

Open Label Immunotherapy of Endometriosis

Endometriosis

Mongolia

Clinical Trials Sponsored by Biocerna LLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations